Joint statement of the Spanish society of digestive pathology and the Spanish society of pharmacology on treatment with biosimilars in inflammatory bowel disease;Posición conjunta de la sociedad Española de patología digestiva y de la sociedad Española de farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal

Revista Espanola de Enfermedades Digestivas

Volumn 105, Issue 1, 2013, Pages 37-43

  Argüelles Arias, Federico ^a   Barreiro de Manuel, Acosta ^a   Carballo, Fernando ^a   Hinojosa, Joaquín ^a   Tejerina, Teresa ^a  

^a Grupo de Trabajo Multidisciplinar en Biosimilares   (Spain)

Author keywords

Adalimumab; Biosimilars; Crohn's disease; Inflammatory bowel disease; Infliximab; Spanish Society of Gastroenterology; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; ERYTHROPOIETIN; ETANERCEPT; GOLIMUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; RECOMBINANT DNA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB; VEDOLIZUMAB;

ARTICLE; BIOTECHNOLOGY; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ENTERITIS; HUMAN; LEUKOENCEPHALOPATHY; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; PATENT; PRACTICE GUIDELINE; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; VALIDATION PROCESS;

EID: 84878532312     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/s1130-01082013000100006     Document Type: Article

References (50)

1. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-97.
2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
3. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Dlchier JC, et al; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroiddependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054-61.
4. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.
5. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33.
6. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med 2007;146:829-38.
7. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
9. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65.
10. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
12. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
13. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med 2004;350:876-85.
14. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009;58:940-8.
15. Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 2006;22:361-4.
16. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001;7:83-8.
17. Probert CJ, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 2003;52:998-1002.
18. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
19. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
20. Barreiro-de Acosta M, Lorenzo A, Dominguez-Muñoz JE. Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009;15:3814-6.
21. Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: A single-centre experience. Aliment Pharmacol Ther 2008;28:966-72.
22. Reinisch W, Sandborn WJ, Hommes D, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
23. Gomollón F, García-López S, Sicilia B, Gisbert J, Hinojosa J, on behalf of GETECCU. The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. Gastroenterol Hepatol 2013 Jan 8. pii: S0210-5705(12)00306-8.
24. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201-11.
25. Sandborn WJ, Van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.
26. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
27. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-28.
28. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007;132:1672-83.
29. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
30. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9.
31. ClinicalTrials.gov. A study of the safety and effectiveness of CNTO 148 (golimumab) in patients with moderately to severely active ulcerative colitis (CR014179). NCT00488631. [Consultado 20/01/2013]. Disponible en: http://clinicaltrials.gov/ct2/show/NCT00488631?term=NCT00488631&rank=1).
32. Hommes D, Colombel J.F, Emery P, Greco M, Sandborn WJ. Changing Crohn's disease management: Need for new goals and indices to prevent disability and improve quality of life. J Crohn's Colitis 2012;6:S224-34.
33. Panaccione R, Hibi T, Peyrin-Biroulet L, Schreiber S. Implementing changes in clinical practice to improve the management of Crohn's disease. J Crohn's Colitis 2012;6:S235-42.
34. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42.
35. Van Maanen, MA, Vervoordeldonk MJ, Tak PP. The cholinergic antiinflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009;5:229-32.
36. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65.
37. Frank DN, St Amand AL, Feldman RA, Boedeker CE, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780-5.
38. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: A systematic review. Gut 2012;61:1619-35.
39. Casellas F. Crohn's disease, feeling well or healthy? Rev Esp Enferm Dig 2010;102:621-3.
40. Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24:762-79.
41. Higgins CH. Biological products. Can Med Assoc J 1912;2:114-20.
42. Brown KR. The regulation of biological products. Eur J Clin Microbiol Infect Dis 1990;9:502-5.
43. Ahmed I, Kaspar B, Sharma U. Biosimilars: Impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012;34:400-19.
44. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91.
45. Pavlovic M, Girardin E, Kapetanovic L, Ho K, Trouvin JH. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Horm Res 2008;69:14-21.
46. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005. 2006. [Consultado 20/01/2013]. Disponible en: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003920.
47. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. EMA/CHMP /BMWP/403543/2010. 2012. [Consultado 20/01/2013]. Disponible en: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500128686.
48. Yi S, Kim SE, Park MK, Yoon SH, Cho JY, Lim KS, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in health volunteers. BioDrugs 2012;26:177-84.
49. American College of Rheumatology. [Consultado 20/01/2010] Disponible en: http://www.rheumatology.org/practice/clinical/position/biosimilars.pdf.
50. Espinosa Morales R, Díaz Borjón A, Barile Fabris LA, Esquivel Valerio JA, Medrano Ramírez G, Arce Salinas CA, et al. Biosimilar drugs in Mexico: Position of the Mexican College of Rheumatology, 2012. Reumatol Clin 2013;9:113-6